IANS: According to a new study published in The Lancet Infectious Diseases, after being vaccinated with Pfizer or AstraZeneca, one in four people will experience mild and short-term systemic side effects, such as headaches, fatigue and pain.
Researchers at King’s College London said the vaccine lasts 24 hours after vaccination, usually one to two days, especially for women under 55. These data should convince many people that the effects of vaccination in the real world are usually mild and short-lived, especially for people over 50 who are at higher risk of infection.
The research team analyzed data from 627,383 users from the ZOE Covid Symptom Study who reported receiving one or two doses of Pfizer vaccine or one dose of AstraZeneca between December 8 and March 10 Systemic and local effects. The results showed that 25.4% of vaccinators reported one or more systemic symptoms (excluding the injection site) and side effects, while 66.2% reported one or more local secondary symptoms (at the injection site).
Approximately 13.5% of participants reported side effects after the first dose, 22.0% after the second Pfizer dose, and 33%.7% after taking AstraZeneca for the first time. The most common systemic side effect is headache: 7.8% of people after taking Pfizer for the first time, 13.2% after taking Pfizer for the second time, and 22.8% of people after taking Pfizer for the first time. According to the researchers, 2% and 50.9% of people reported pain after the first and second injection of Pfizer vaccine, and 49.3% of people reported pain after the first injection of AstraZeneca vaccine.
The study also reported a significant reduction in infection rates from 12 days to 21 days. Compared with the control group, after the first use of Pfizer (a reduction of 58%) and AstraZeneca (a reduction of 39%), the reduction in infections at least 21 days after the first use of Pfizer was 69% and AstraZeneca 60 after taking the Pfizer vaccine.
People with the Covid vaccine are three times more likely to have systemic side effects than patients with unknown infections, and they are almost twice as likely to take the AstraZeneca vaccine for the first time.